Pharmacy Times®
Specialty Pharmacy Times
  • Top 10 Trends in Specialty Pharmacy
  • The Specialty Pharmacy’s Role in Ensuring the Effectiveness of New Hepatitis C Drugs
  • Co-pay Coupons Are No Bargain for Specialty Pharmacies
  • Specialty Pipeline Highlights
  • Newly Approved Oncology Agents
  • Generic Drug Labeling Issues: How They Could Affect Biosimilars
Breast Cancer Prevention Drug Risks Outweigh Benefits for Most Women
Davy James, Associate Editor
Benefits of tamoxifen varies among patients.
Multiple Sclerosis Cognitive Fatigue Affected by Task Length
Davy James, Associate Editor
Researchers gain insight into the cause of fatigue in MS patients.
Melanoma Becomes Resistant to New Combination Therapy Through Genetic Changes
Davy James, Associate Editor
Researchers discover how cancer resists BRAF+MEK inhibitors.
Perjeta by Genentech, Inc
Michael R. Page, PharmD, RPh
Perjeta (pertuzumab) is now approved for the neoadjuvant treatment of breast cancer.
Cyramza by Eli Lilly
Michael R. Page, PharmD, RPh
Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.
Featured Video
The Changing Landscape of Limited Distribution Specialty Drugs
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developing trends in the limited distribution of specialty medications.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        January 2015        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.